Xenios AG
Clinical trials sponsored by Xenios AG, explained in plain language.
Medical device company specializing in extracorporeal organ support systems.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Mini lung machine tested on tiniest patients Results expected Oct 2026 (estimated)
- New ECMO device tested for safe transport of critically ill patients Results expected Apr 2027 (estimated)
-
New ECMO device tested for safe transport of critically ill patients
Disease control Recruiting nowThis study will test a new medical device kit (Novalung ultimate kit with Xenios 2.0) in 20 adult patients with severe heart-lung failure who need ECMO life support. The goal is to see if the device safely and effectively maintains blood oxygen levels during hospital use and grou…
Sponsor: Xenios AG • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Mini lung machine tested on tiniest patients
Disease control Recruiting nowThis study is testing a small device called the MiniLung petite kit, which helps oxygenate blood and remove carbon dioxide in newborns and children weighing 2 to 8 kilograms who have severe breathing or heart failure. The device works with a console to temporarily take over the w…
Sponsor: Xenios AG • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC